Find links to pertinent regulatory and standard setting resources, guidance documents, and guidelines.
Find links to pertinent regulatory and standard setting resources, guidance documents, and guidelines.
View this resource in BioPharm International’s September 2019 Regulatory Sourcebook.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.